Acute radiation syndrome (ARS) - treatment of the reduced host defense

International Journal of General Medicine

Volumn 5, Issue , 2012, Pages 105-115

  Heslet, Lars ^a   Bay, Christiane ^b   Nepper Christensen, Steen ^c  

^a Serendex ApS   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Køge University Hospital   (Denmark)

Author keywords

ARS; Host defense; Inhaled and systemically administered GM CSF; Orchestration of pulmonary host response

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE RADIATION SYNDROME; ANTIBIOTIC PROPHYLAXIS; BONE PAIN; CELL FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; DENDRITIC CELL; DOSIMETRY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; GASTROINTESTINAL DISEASE; GRANULOCYTE; HEMATOLOGIC DISEASE; HOST RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IONIZING RADIATION; LUNG DISEASE; MACROPHAGE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PSYCHOSOCIAL CARE; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; SYMPTOMATOLOGY; ACUTE DISEASE; BONE MARROW SUPPRESSION; CAUSE OF DEATH; CONVALESCENCE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; DRUG WITHDRAWAL; FEVER; IMMUNOCOMPETENT CELL; INFECTION; INFECTION PREVENTION; INJURY SEVERITY; NEUTROPENIA; PROPHYLAXIS; SURVIVAL RATE; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TREATMENT PLANNING;

EID: 84857099693     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S22177     Document Type: Review

References (60)

1. Radiation injury. In: Fauci AS, Braunwald E, Kasper DL, et al, editors. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill Professional; 2008:2559-2568.
2. Hall EJ. Acute effects of total-body irradiation. In: Hall EJ. Radiobiology for the Radiologist. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2000:117-128.
3. Cerveny TJ, MacVittie TJ, Young RW. Acute radiation syndrome in humans. In: Walker RI, Cerveny TJ, editors. Medical Consequences of Nuclear Warfare. 1989. Falls Church, VA: TMM Publications, Office of the Surgeon General; 1989:17-36.
4. Anno GH, Baum SJ, Withers HR, Young RW. Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy. Health Phys. 1989;56(6):821-838.
5. Mettler FA Jr, Gus'kova AK, Gusev I. Health effects in those with acute radiation sickness from the Chernobyl accident. Health Phys. 2007;93(5):462-469.
6. Thongpraparn T, Chaudakshetrin P, Buranapong P. Lesson learned from Co-60 accident in Thailand. Australas Phys Eng Sci Med. 2002;25(4):172-174.
7. Liu Q, Jiang B, Jiang LP, et al. Clinical report of three cases of acute radiation sickness from a (60)Co radiation accident in Henan Province in China. J Radiat Res (Tokyo). 2008;49(1):63-69.
8. Gourmelon P, Benderitter M, Bertho JM, Huet C, Gorin NC, De Revel P. European consensus on the medical management of acute radiation syndrome and analysis of the radiation accidents in Belgium and Senegal. Health Phys. 2010;98(6):825-832.
9. Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med. 2004;140(12):1037-1051.
10. Junk AK, Egner P, Gottloeber P, Peter RU, Stefani FH, Kellerer AM. Long-term radiation damage to the skin and eye after combined beta- and gamma- radiation exposure during the reactor accident in Chernobyl. Klin Monbl Augenheilkd. 1999;215(6):355-360. German.
11. Donnelly EH, Nemhauser JB, Smith JM, et al. Acute radiation syndrome: assessment and management. South Med J. 2010;103(6):541-546.
12. Schull WJ. Effects of Atomic Radiation. New York, NY: Wiley-Liss; 1995.
13. Weisdorf D, Chao N, Waselenko JK, et al. Acute radiation injury: contingency planning for triage, supportive care, and transplantation. Biol Blood Marrow Transplant. 2006;12(6):672-682.
14. Butturini A, De Souza PC, Gale RP, et al. Use of recombinant granulocyte- macrophage colony stimulating factor in the Brazil radiation accident. Lancet. 1988;2(8609):471-475.
15. Brandão-Mello CE, Oliveira AR, Valverde NJ, Farina R, Cordeiro JM. Clinical and hematological aspects of 137Cs: the Goiânia radiation accident. Health Phys. 1991;60(1):31-39.
16. Nagler A, Naparstek E, Drakos P, et al. Interleukin-3 in combination with granulocyte-macrophage-colony-stimulating factor following bone marrow transplantation in a radiation accident victim. Med Oncol. 1994;11(1):27-28.
17. Baranov AE, Selidovkin GD, Butturini A, Gale RP. Hematopoietic recovery after 10-Gy acute total body radiation. Blood. 1994;83(2):596-599.
18. Vorobiev AI. Acute radiation disease and biological dosimetry in 1993. Stem Cells. 1997;15 Suppl 2:269-274.
19. Fliedner TM, Andrews GA, Cronkite EP, Bond VP. Early and late cytologic effects of whole body irradiation on human marrow. Blood. 1964;23:471-487.
20. Fliedner T, Cronkite E, Bond VP. Assessment of radiation effects by molecular and cellular approaches. Stem Cells. 1995;(Suppl 1):13.
21. Fliedner TM. Nuclear terrorism: the role of hematology in coping with its health consequences. Curr Opin Hematol. 2006;13(6):436-444.
22. Gurion R, Gafter-Gvili A, Paul M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009;94(5):712-719.
23. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res. 1999;5(9):2316-2323.
24. Wylam ME, Ten R, Prakash UB, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J. 2006;27(3):585-593.
25. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
26. Weisbart RH, Gasson JC, Golde DW. Colony-stimulating factors and host defense. Ann Intern Med. 1989;110(4):297-303.
27. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood. 1996;88(10):3675-3685.
28. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocytemacrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324(25):1773-1778.
29. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol. 1995;13(6):1323-1327.
30. Ciernik IF, Schanz U, Gmür J. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant. 1999;24(2):147-151.
31. Demirer T, Ayli M, Dagli M, et al. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol. 2002;118(4):1104-1111.
32. Bence-Bruckler I, Bredeson C, Atkins H, et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant. 1998;22(10):965-969.
33. Mayer P, Schütze E, Lam C, Kricek F, Liehl E. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis. 1991;163(3):584-590.
34. Rose RM, Kobzik L, Dushay K, et al. The effect of aerosolized recombinant human granulocyte macrophage colony-stimulating factor on lung leukocytes in nonhuman primates. Am Rev Respir Dis. 1992;146(5 Pt 1):1279-1286.
35. Neelis KJ, Dubbelman YD, Qingliang L, Thomas GR, Eaton DL, Wagemaker G. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol. 1997;25(10):1084-1093.
36. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiationinduced marrow aplasia. J Clin Invest. 1996;97(9):2145-2151.
37. MacVittie TJ, Farese AM, Herodin F, Grab LB, Baum CM, McKearn JP. Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor. Blood. 1996;87(10): 4129-4135.
38. Neelis KJ, Hartong SC, Egeland T, Thomas GR, Eaton DL, Wagemaker G. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood. 1997;90(7):2565-2573.
39. Farese AM, Williams DE, Seiler FR, MacVittie TJ. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood. 1993;82(10):3012-3018.
40. Schuening FG, Appelbaum FR, Deeg HJ, et al. Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood. 1993;81(1):20-26.
41. Schuening FG, Storb R, Goehle S, et al. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood. 1989;74(4):1308-1313.
42. Nash RA, Schuening FG, Seidel K, et al. Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood. 1994;83(7):1963-1970.
43. Bertho JM, Roy L, Souidi M, et al. New biological indicators to evaluate and monitor radiation-induced damage: an accident case report. Radiat Res. 2008;169(5):543-550.
44. Bertho JM, Roy L. A rapid multiparametric method for victim triage in cases of accidental protracted irradiation or delayed analysis. Br J Radiol. 2009;82(981):764-770.
45. Prasanna PG, Blakely WF, Bertho JM, et al. Synopsis of partial-body radiation diagnostic biomarkers and medical management of radiation injury workshop. Radiat Res. 2010;173(2):245-253.
46. Léonard A, Rueff J, Gerber GB, Léonard ED. Usefulness and limits of biological dosimetry based on cytogenetic methods. Radiat Prot Dosimetry. 2005;115(1-4):448-454.
47. Sevan'kaev AV, Golub EV, Khvostunov IK, et al. Retrospective dose estimation in remote period after exposure using different biological methods. Radiats Biol Radioecol. 2004;44(6):637-652. Russian.
48. Heslet L. Look on the "air side" in pneumonia. Crit Care Med. 2009; 37(2):774-775.
49. Brand P, Beckmann H, Maas Enriquez M, et al. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J. 2003;22(2):263-267.
50. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008;178(6):618-623.
51. Heslet L, Andersen JS, Sengeløv H, Dahlbäck B, Dalsgaard-Nielsen J. Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome. Biologics. 2007;1(4):465-472.
52. Waerhaug K, Kuzkov VV, Kuklin VN, et al. Inhaled aerosolized recombinant human activated protein C ameliorates endotoxin-induced lung injury in anaesthetised sheep. Crit Care. 2009;13(2):R51.
53. Sangwan S, Agosti JM, Bauer LA, et al. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. J Aerosol Med. 2001;14(2):185-195.
54. Luisetti M, Kroneberg P, Suzuki T, et al. Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer. Pulm Pharmacol Ther. 2011;24(1):123-127.
55. Robinson TE, Trapnell BC, Goris ML, Quittell LM, Cornfield DN. Quantitative analysis of longitudinal response to aerosolized granulocytemacrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Chest. 2009;135(3):842-848.
56. Price A, Manson D, Cutz E, Dell S. Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF. Pediatr Pulmonol. 2006;41(4):367-370.
57. Rao RD, Anderson PM, Arndt CA, Wettstein PJ, Markovic SN. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol. 2003;26(5):493-498.
58. Belyi D, Kovalenko A, Bazyka D, Bebeshko V. Non-cancer effects in acute radiation syndrome survivors in Ukraine. Health Phys. 2010;98(6):876-884.
59. Baranov A, Gale RP, Guskova A, et al. Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med. 1989;321(4): 205-212.
60. Gale RP, Reisner Y. The role of bone-marrow transplants after nuclear accidents. Lancet. 1988;1(8591):923-926.